当前位置: X-MOL 学术Vet. Comp. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Safety evaluation of the canine osteosarcoma vaccine, live Listeria vector
Veterinary and Comparative Oncology ( IF 2.3 ) Pub Date : 2020-07-30 , DOI: 10.1111/vco.12642
Margaret L Musser 1 , Erika P Berger 1 , Chelsea D Tripp 2 , Craig A Clifford 3 , Philip J Bergman 4, 5 , Chad M Johannes 1
Affiliation  

Canine osteosarcoma (OSA) is an aggressive bone tumour in dogs. Standard‐of‐care treatment typically results in relatively short survival times; thus, alternative treatments are needed to confer a survival advantage. It has been shown that OSA is an immunogenic tumour, suggesting that immune modulation may result in superior outcomes. A cryopreserved, Listeria‐based OSA vaccine was recently developed and an initial study in dogs reported prolonged survival for patients receiving the vaccine in conjunction with standard‐of‐care. The goal of the current observational study was to report on the safety of the lyophilized formulation of this vaccine (the canine OSA vaccine, live Listeria vector [COV‐LLV]) in a group of dogs previously diagnosed with OSA. Forty‐nine (49) dogs received the COV‐LLV and were included for analysis. Adverse events (AEs) noted during and after vaccinations were recorded. The AEs observed were typically mild and self‐limiting, with nausea, lethargy and fever being most common. Four dogs (8%) cultured positive for Listeria (three infections including an amputation site abscess, septic stifle joint and bacterial cystitis; and one dog whose lungs cultured Listeria‐positive on necropsy within 24 hours of COV‐LLV administration). These cases join the previously reported Listeria‐positive thoracic abscess that developed in a canine following use of COV‐LLV. Although uncommon, it is important to realize this clinically significant AE is possible in patients treated with live therapeutic Listeria vaccines. As Listeria is zoonotic, caution is required not only for the patient receiving the vaccine, but also for the health care workers and family caring for the patient.

中文翻译:

犬骨肉瘤疫苗,活李斯特菌载体的安全性评估

犬骨肉瘤(OSA)是犬的侵袭性骨肿瘤。护理标准治疗通常会导致相对较短的生存时间;因此,需要其他治疗以赋予生存优势。已经显示OSA是免疫原性肿瘤,表明免疫调节可导致更好的结果。最近开发了一种低温保存的,基于李斯特菌的OSA疫苗,一项针对狗的初步研究报告说,与标准护理相结合,接受该疫苗的患者的生存期更长。当前观察研究的目的是报告该疫苗冻干制剂(犬OSA疫苗,活李斯特菌)的安全性载体[COV-LLV])在先前被诊断为OSA的一组狗中。四十九(49)只狗接受了COV-LLV并被纳入分析。记录疫苗接种期间和之后的不良事件(AE)。观察到的AE通常为轻度且自限性,最常见的是恶心,嗜睡和发烧。四只(8%)的狗培养出李斯特菌阳性(三处感染,包括截肢脓肿,化脓性窒息性关节炎和细菌性膀胱炎;另一只狗的肺在验尸后24小时内尸检时李斯特菌呈阳性)。这些病例加入了先前报道的李斯特菌使用COV-LLV后犬体内出现的阳性胸腔脓肿。尽管不常见,但重要的是要认识到用活的治疗李斯特菌疫苗治疗的患者可能具有临床上显着的不良事件。由于李斯特菌是人畜共患病的,因此不仅需要对接受疫苗的患者保持谨慎,而且还需要对医护人员和照顾患者的家人进行谨慎。
更新日期:2020-07-30
down
wechat
bug